Subacute polyneuropathy of a patient under treatment with disulfiram, suffering from alcohol use disorder

1 Vasan S, Kumar A. Wernicke Encephalopathy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; August 8, 2022. Search in Google Scholar

2 Sandbrink, F. (2014). Weakness, paraparesis. In A. Ettinger & D. Weisbrot (Eds.), Neurologic Differential Diagnosis: A Case-Based Approach (pp. 528-536). Cambridge: Cambridge University Press. Search in Google Scholar

3 Waespe W, Vogel Wigger BM, Bächli E, Boltshauser E. Differentialdiagnostische Aspekte der progredienten spastischen Paraparese beim Erwachsenen mit Betonung neurometabolischer Erkrankungen [Differential diagnostic aspects of progressive spastic paraplegia in adults with emphasis on neurometabolic diseases]. Praxis (Bern 1994). 1995 Apr 18;84(16):473-7. German. Search in Google Scholar

4 Agarwal S, Biagioni MC. Essential Tremor. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 10, 2023. Search in Google Scholar

5 Kusanale A, Wilson A, Brennan P. Tongue tremor: a rare initial presentation of essential tremor. Br J Oral Maxillofac Surg. 2011;49(8):e82-e83. doi:10.1016/j.bjoms.2011.05.006 Search in Google Scholar

6 Biary N, Koller WC. Essential tongue tremor. Mov Disord. 1987;2(1):25-29. doi:10.1002/mds.870020103 Search in Google Scholar

7 Koller WC, Glatt S, Biary N, Rubino FA. Essential tremor variants: effect of treatment. Clin Neuropharmacol. 1987;10(4):342-350. doi:10.1097/00002826-198708000-00004 Search in Google Scholar

8 Younger DS, Brown RH Jr. Amyotrophic lateral sclerosis. Handb Clin Neurol. 2023;196:203-229. doi:10.1016/B978-0-323-98817-9.00031-4 Search in Google Scholar

9 Jaulent P, Laurencin C, Robert H, Thobois S. Parkinson’s Disease Revealed by a Resting Tongue Tremor. Mov Disord Clin Pract. 2015 Aug 24;2(4):432-433. doi: 10.1002/mdc3.12202. PMID: 30363535; PMCID: PMC6178599. Search in Google Scholar

10 Delil Ş, Bölükbaşı F, Yeni N, Kızıltan G. Re-emergent Tongue Tremor as the Presenting Symptom of Parkinson’s Disease. Balkan Med J. 2015 Jan;32(1):127-8. doi: 10.5152/balkanmedj. 2015.15008. Epub 2015 Jan 1. PMID: 25759787; PMCID: PMC4342128. Search in Google Scholar

11 Numao A, Suzuki K, Fujita H, et alResting and re-emergent tongue tremor in Parkinson’s diseaseCase Reports 2017;2017:bcr-2017-221808. Search in Google Scholar

12 Jones KS, Saylam E, Ramphul K. Tourette Syndrome and Other Tic Disorders. In: StatPearls. Treasure Island (FL): StatPearls Publishing; May 8, 2023. Search in Google Scholar

13 Rucker JC. Normal and abnormal lid function. Handb Clin Neurol. 2011;102:403-424. doi:10.1016/B978-0-444-52903-9.00021-2 Search in Google Scholar

14 Zawar I, Knight EP. Epilepsy With Eyelid Myoclonia (Jeavons Syndrome). Pediatr Neurol. 2021;121:75-80. doi:10.1016/j. pediatrneurol.2020.11.018 Search in Google Scholar

15 The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. (2018). Search in Google Scholar

16 Burnette EM, Nieto SJ, Grodin EN, Meredith LR, Hurley B, Miotto K, Gillis AJ, Ray LA. Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder. Drugs. 2022 Feb;82(3):251-274. Search in Google Scholar

17 Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, Garbutt JC. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014 May 14;311(18):1889-900. Search in Google Scholar

18 Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kämpf P, Stracke R, Baehr M, Naber D, Wiedemann K. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003 Jan;60(1):92-9. Search in Google Scholar

19 Mann K, Roos CR, Hoffmann S, Nakovics H, Leménager T, Heinz A, Witkiewitz K. Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes. Neuropsychopharmacology. 2018 Mar;43(4):891-899. Search in Google Scholar

20 Ray LA, Chin PF, Miotto K. Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disord Drug Targets. 2010 Mar;9(1):13-22. Search in Google Scholar

21 Pettinati HM, O’Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol. 2006 Dec;26(6):610-25. Search in Google Scholar

22 Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013 Feb;108(2):275-93. Search in Google Scholar

23 Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol. 2014 Feb;77(2):315-23. Search in Google Scholar

24 Higuchi S; Japanese Acamprosate Study Group. Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study). J Clin Psychiatry. 2015 Feb;76(2):181-8. Search in Google Scholar

25 Plosker GL. Acamprosate: A Review of Its Use in Alcohol Dependence. Drugs. 2015 Jul;75(11):1255-68. Search in Google Scholar

26 Manhapra A, Chakraborty A, Arias AJ. Topiramate Pharmacotherapy for Alcohol Use Disorder and Other Addictions: A Narrative Review. J Addict Med. 2019 Jan/Feb;13(1):7-22. Search in Google Scholar

27 Shank RP, Maryanoff BE. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther. 2008 Summer;14(2):120-42. Search in Google Scholar

28 Mason BJ, Quello S, Shadan F. Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs. 2018 Jan;27(1):113-124. Search in Google Scholar

29 Roberto M, Gilpin NW, O’Dell LE, Cruz MT, Morse AC, Siggins GR, Koob GF. Cellular and behavioral interactions of gabapentin with alcohol dependence. J Neurosci. 2008 May 28;28(22):5762-71. Search in Google Scholar

30 Roberto M, Cruz MT, Gilpin NW, Sabino V, Schweitzer P, Bajo M, Cottone P, Madamba SG, Stouffer DG, Zorrilla EP, Koob GF, Siggins GR, Parsons LH. Corticotropin releasing factor-induced amygdala gamma-aminobutyric Acid release plays a key role in alcohol dependence. Biol Psychiatry. 2010 May 1;67(9):831-9. Search in Google Scholar

31 Williams JB. Use of Disulfiram for Treatment of Alcohol Addiction in Patients with Psychotic Illness. Am J Psychiatry. 2019 Jan 1;176(1):80-81. Search in Google Scholar

32 Williams EC, Matson TE, Harris AHS. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions. Addict Sci Clin Pract. 2019 Feb 12;14(1):6. Search in Google Scholar

33 Heldal AT, Skurtveit S, Lobmaier PPK, Vederhus JK, Bramness JG. Bruk av medikamenter for alkoholbrukslidelser i Norge 2004–16 [Use of drugs for alcohol use disorder in Norway 2004–16]. Tidsskr Nor Laegeforen. 2018 Nov 8;138(18). Norwegian. Search in Google Scholar

34 Ait-Daoud N, Johnson BA. Medications for the treatment of alcoholism. In: Handbook of Clinical Alcoholism Treatment, Johnson BA, Ruiz P, Galanter M (Eds), Lippincott Williams & Wilkins, Baltimore 2003. p.119. Search in Google Scholar

35 Guerzoni S, Pellesi L, Pini LA, Caputo F. Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review. Pharmacol Res. 2018 Jul;133:65-76. Search in Google Scholar

36 Kranzler HR, Soyka M. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review. JAMA. 2018 Aug 28;320(8):815-824. Search in Google Scholar

37 Blanco-Gandía MC, Rodríguez-Arias M. Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years. Eur J Pharmacol. 2018 Oct 5;836:89-101. Search in Google Scholar

38 Frisoni GB, Di Monda V. Disulfiram neuropathy: a review (1971-1988) and report of a case. Alcohol Alcohol. 1989;24(5):429-37. Search in Google Scholar

39 Mohapatra S, Sahoo MR, Rath N. Disulfiram-induced neuropathy: a case report. Gen Hosp Psychiatry. 2015 Jan-Feb;37(1):97.e5-6. Search in Google Scholar

40 Filosto M, Tentorio M, Broglio L, Buzio S, Lazzarini C, Pasolini MP, Cotelli MS, Scarpelli M, Mancuso M, Choub A, Padovani A. Disulfiram neuropathy: two cases of distal axonopathy. Clin Toxicol (Phila). 2008 Apr;46(4):314-6. Search in Google Scholar

41 Tran AT, Rison RA, Beydoun SR. Disulfiram neuropathy: two case reports. J Med Case Rep. 2016 Mar 31;10:72. Search in Google Scholar

42 Watson CP, Ashby P, Bilbao JM. Disulfiram neuropathy. Can Med Assoc J. 1980 Jul 19;123(2):123-6. Search in Google Scholar

43 Moddel G, Bilbao JM, Payne D, Ashby P. Disulfiram Neuropathy. Arch Neurol. 1978;35(10):658–660. Search in Google Scholar

44 Mokri B, Ohnishi A, Dyck PJ. Disulfiram neuropathy. Neurology. 1981 Jun;31(6):730-5. Search in Google Scholar

45 Bergouignan FX, Vital C, Henry P, Eschapasse P. Disulfiram neuropathy. J Neurol. 1988 Jul;235(6):382-3. Search in Google Scholar

46 Behan C, Lane A, Clarke M. Disulfiram induced peripheral neuropathy: between the devil and the deep blue sea. Ir J Psychol Med. 2007 Sep;24(3):115-116. Search in Google Scholar

47 Vujisić S, Radulović L, Knezević-Apostolski S, Petković S, Vukmirović F, Apostolski S. [Disulfiram-induced polyneurophaty]. Vojnosanit Pregl. 2012 May;69(5):453-7. Serbian. Search in Google Scholar

48 Van Rossum J, Roos RA, Bots GT. Disulfiram polyneuropathy. Clin Neurol Neurosurg. 1984;86(2):81-7. Search in Google Scholar

49 Hammoud, N., & Jimenez-Shahed, J. (2019). Chronic Neurologic Effects of Alcohol. Clinics in Liver Disease, 23(1), 141–155. Search in Google Scholar

50 Fouarge E, Maquet P. Conséquences neurologiques centrales et périphériques de l’alcoolisme [Neurological consequences of alcoholism]. Rev Med Liege. 2019 May;74(5-6):310-313. French. Search in Google Scholar

51 Diamond I, Messing RO. Neurologic effects of alcoholism. West J Med. 1994 Sep;161(3):279-87. Search in Google Scholar

52 Mellion M, Gilchrist JM, de la Monte S. Alcohol-related peripheral neuropathy: nutritional, toxic, or both? Muscle Nerve. 2011 Mar;43(3):309-16. Search in Google Scholar

53 Hammoud, N., & Jimenez-Shahed, J. (2019). Chronic Neurologic Effects of Alcohol. Clinics in Liver Disease, 23(1), 141–155. Search in Google Scholar